Literature DB >> 15455986

Successful ivermectin treatment of hepatic strongyloidiasis presenting with severe eosinophilia.

Zafer Gulbas1, Mahmut Kebapci, Ozgul Pasaoglu, Eser Vardareli.   

Abstract

A 49-year-old, previously healthy nurse presented with hepatic lesions and severe peripheral eosinophilia due to strongyloidiasis. Imaging studies of the abdomen showed predominantly peripheral, confluent hepatic lesions. The hepatic lesions and eosinophilia did not show any improvement with albendazole, but completely resolved with ivermectin treatment. Our findings suggest that Strongyloides stercoralis can present with isolated focal hepatic lesions and severe eosinophilia, and resolves with ivermectin treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15455986     DOI: 10.1097/01.SMJ.0000139936.20116.A7

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  5 in total

Review 1.  Strongyloidiasis: A Neglected Tropical Disease.

Authors:  Alejandro Krolewiecki; Thomas B Nutman
Journal:  Infect Dis Clin North Am       Date:  2019-03       Impact factor: 5.982

Review 2.  Screening, prevention, and treatment for hyperinfection syndrome and disseminated infections caused by Strongyloides stercoralis.

Authors:  Rojelio Mejia; Thomas B Nutman
Journal:  Curr Opin Infect Dis       Date:  2012-08       Impact factor: 4.915

Review 3.  Human infection with Strongyloides stercoralis and other related Strongyloides species.

Authors:  Thomas B Nutman
Journal:  Parasitology       Date:  2016-05-16       Impact factor: 3.234

4.  Strongyloides stercoralis infection in the immunocompromised host.

Authors:  Roshan Ramanathan; Thomas Nutman
Journal:  Curr Infect Dis Rep       Date:  2008-05       Impact factor: 3.725

Review 5.  Severe strongyloidiasis: a systematic review of case reports.

Authors:  Dora Buonfrate; Ana Requena-Mendez; Andrea Angheben; Jose Muñoz; Federico Gobbi; Jef Van Den Ende; Zeno Bisoffi
Journal:  BMC Infect Dis       Date:  2013-02-08       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.